- Overview
- Symptoms
- Causes & Risks
- Tests & Diagnosis
- Treatment
- Living With
- Complications
- Support & Resources
- Appointment Prep
- View Full Guide
Biologic Drugs for Crohn's Disease


Introduction to Biologics
Biologics are prescription drugs that target specific proteins in your body that cause inflammation. Your doctor may prescribe one if other treatments haven't worked.

FDA-Approved Biologics
The FDA has approved several biologic drugs for Crohn's: adalimumab, certolizumab, infliximab, natalizumab, risankizumab, ustekinumab, and vedolizumab. Each targets specific proteins involved in inflammation. Your doctor will give them in a shot or an IV.

Common Side Effects
Side effects of biologics can include reactions where the needle went in your skin, infections, and allergic reactions. The side effects vary based on the specific drug.

Cost of Biologics
Biologic drugs, even generic versions, can be very expensive. They're hard to make and that drives up the price. One year of treatment can add up to about $20,000. Even if you have insurance, you may have to pay up to 35% of the cost.

Making Biologics More Affordable
Many drug companies and private groups offer programs that provide drugs at low or no cost. NeedyMeds can fill you in on more than 2,400 drug aid programs. RxAssist has a list of patient aid programs and drug discount cards. The Crohn's & Colitis Foundation of America can provide other resources.

Reducing Inflammation
Biologics target specific proteins in the inflammatory process, helping to reduce symptoms and achieve remission. Not everyone responds in the same way. Finding the most effective drug with the fewest side effects can take time.

Medication Interactions
Tell your doctor about all prescription and over-the-counter drugs, supplements, or natural remedies you take – and check with your doctor before you take anything new. Any of these can affect the way your medication works.
Photo Credits:
1) ARTFULLY PHOTOGRAPHER/Shutterstock
2) luchschenF/Shutterstock
3) Troyan/Shutterstock
4) SB Arts Media/Shutterstock
5) MOLEOL/Shutterstock
6) Emily frost/Shutterstock
7) Worawee Meepian/Shutterstock
SOURCES:
American College of Gastroenterology, Practice Guidelines: "Management of Crohn's Disease in Adults."
Amgen Prescribing Information, Amjevita.
Crohn's & Colitis Foundation: "Biologic Therapies," "Understanding IBD Medications and Side Effects," "Medications: Biologic Therapy," "About Crohn's Disease."
FDA: “FDA approves Amjevita, a biosimilar to Humira,” “FDA approves Inflectra, a biosimilar to Remicade,” "Prescribing Information, Infliximab-dyyb (Inflectra)," "Facts and Myths About Generic Drugs."
American Academy of Allergy, Asthma & Immunology: "Medications and Drug Allergic Reactions: Tips to Remember."
Stelara Prescribing Information.
Expert Opinion on Biological Therapy: "Overview of biologic therapy for Crohn's disease."
American Medical News: "Health reform law gives biologic drugs 12-year exclusivity."
The New England Journal of Medicine: "Balancing Innovation, Access, and Profits – Market Exclusivity for Biologics."
Society of Actuaries: "Infliximab therapy for individuals with Crohn's disease: Analysis of health care utilization and expenditures."
Journal of Generic Medicines: "Biological Generics: A Business Case."
Forbes: "Why Biologics Remain Expensive."
Gastroenterology & Endoscopy News: "Skyrizi Approved for Crohn's Disease Treatment."
Skyrizi.com: "Skyrizi Dosing."